"HCT-15人結(jié)直腸腺癌復(fù)蘇細(xì)胞保種中心|帶STR證書

傳代比例：1:2-1:4(首次傳代建議1:2)

生長特性：貼壁生長

細(xì)胞復(fù)蘇后貼壁細(xì)胞較少的問題分析：總結(jié)１：復(fù)蘇過程沒有問題，是否是從拿出直接放入溫水，還有培養(yǎng)箱，二氧化碳濃度，培養(yǎng)基、PH值等環(huán)節(jié)。要么加GAO濃度FBS １５-２０%，看看能否幫助貼壁，當(dāng)然也需要考慮血清問題，還有確信拿來的細(xì)胞沒問題?？偨Y(jié)２：首先應(yīng)該懷疑凍存，實際上復(fù)蘇出問題的可能非常小，因為操作簡單，而且死板。１、你凍存的時候是不是消化的時間過長，這是一般人所注意不到的，即使書上也不講這個問題，太長的消化時間會讓細(xì)胞復(fù)蘇時失去貼壁能力，表現(xiàn)為先貼后死，原因是在你復(fù)蘇的時候細(xì)胞已進入凋亡程序，不可逆轉(zhuǎn)的死亡。２、你的凍存HAO不HAO，是什么，甘油還是DMSO，質(zhì)量非常重要，否則也會死亡。３、你的凍存的量加的是不是太多，AC推薦是不超過７%，大于５%，太多也不HAO。４、你在凍存的時候是不是把DMSO混均勻，這個有一些影響，但不算太大。５、你的凍存是否按部就班，就是所溫度梯度是不是把握嚴(yán)格，很多人容易忘卻這個事情，因為這個東西流程長。６、如果你細(xì)胞污染，你是否能很快看到，我比我的導(dǎo)師能早一天看到污染。從這個角度講建議去除離心這步。７、你的細(xì)胞在凍存前是否過密。還有，不贊成孵箱污染這個概念的，所有在一個孵箱里的細(xì)胞都污染一個細(xì)菌的話，這個細(xì)菌是源于孵箱的，但這不代表孵箱污染，因為孵箱無論你如何處理都有大量的細(xì)菌，問題在操作。每次污染的原因都要盡可能的找，以后就不犯同樣的問題，這個很重要，不能靠猜，否則你就有可能細(xì)胞養(yǎng)絕Zui后換課題，這個見得太多了，別不當(dāng)會事。

換液周期：每周2-3次

KU-812-F Cells;背景說明：慢性粒細(xì)胞白血??；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SEM細(xì)胞、Mevo細(xì)胞、OCIAML2細(xì)胞

RPMI 7666 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：DMS 53細(xì)胞、SR-786細(xì)胞、SN12C-PM6細(xì)胞

MN 60 Cells;背景說明：B細(xì)胞白血??；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCI-H719細(xì)胞、639-V細(xì)胞、MZCRC1細(xì)胞

HCT-15人結(jié)直腸腺癌復(fù)蘇細(xì)胞保種中心|帶STR證書

背景信息：是一種人結(jié)直腸腺癌細(xì)胞系，最初分離自一名男性結(jié)直腸腺癌患者的癌組織。DNA指紋鑒定證據(jù)表明，HCT-15細(xì)胞和DLD-1細(xì)胞來源于同一個人；但同工酶及細(xì)胞染色體組型分析仍存疑問。HCT-15細(xì)胞呈CSAp陰性(CSAp-)；HCT-15角蛋白免疫過氧化物酶染色陽性。

【細(xì)胞培養(yǎng)經(jīng)驗分享】啟蒙老師的重要性：一般進實驗室都有師兄師姐帶著做，他們就是你做細(xì)胞的啟蒙老師。他們的操作手法、細(xì)節(jié)、理論講解就成了你操作的準(zhǔn)則，如營養(yǎng)液、細(xì)胞瓶的擺放位置、滅菌處理程序、開蓋手法、細(xì)胞吹打手法等等。要學(xué)會他們的正確操作，在第一次的時候就要重視。像養(yǎng)孩子一樣養(yǎng)細(xì)胞，細(xì)胞有時真的很脆弱，最好每天都去看看它，以防止出現(xiàn)培養(yǎng)箱缺水、缺二氧化碳、停電、溫度不夠等異?，F(xiàn)象，也好及時解決這些意外，避免重復(fù)實驗帶來的更大痛苦。好細(xì)胞要及時保種：細(xì)胞要分批傳代，這樣即使有一批出了問題，還有一批備用的。像后者一般人可能不容易做到。但這是我血的教訓(xùn)，有一次細(xì)胞污染了，全軍覆沒。當(dāng)時可后悔沒有保種。細(xì)胞跟人一樣，不同的細(xì)胞，培養(yǎng)特性是不一樣的。培養(yǎng)過程中要細(xì)細(xì)體會，不同細(xì)胞系使用不同的培養(yǎng)基和血清。

產(chǎn)品包裝：復(fù)蘇發(fā)貨：T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨：1ml凍存管(兩支)

來源說明：細(xì)胞主要來源ATCC、ECACC、DSMZ、RIKEN等細(xì)胞庫

GM3570 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HS-729細(xì)胞、OCILY10細(xì)胞、GM02132細(xì)胞

WSU-DLCL(2) Cells;背景說明：彌漫大B淋巴瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MDCK細(xì)胞、V 79-4細(xì)胞、HCV 29細(xì)胞

HUT-226 Cells;背景說明：１９８０年分離建立。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：RCC23細(xì)胞、COLO-699細(xì)胞、OVCAR10細(xì)胞

QSG-7701 Cells;背景說明：該細(xì)胞系來自３５歲女性的肝癌癌旁組織。;傳代方法：消化３-５分鐘，１：２,３天內(nèi)可長滿;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：SW 626細(xì)胞、Y3-Ag1.2.3細(xì)胞、RPTC細(xì)胞

HCT-15人結(jié)直腸腺癌復(fù)蘇細(xì)胞保種中心|帶STR證書

物種來源：人源、鼠源等其它物種來源

形態(tài)特性：上皮細(xì)胞樣

細(xì)胞凍存知識普及：細(xì)胞凍存是細(xì)胞保存的主要方法之一。利用凍存技術(shù)將細(xì)胞置于-１９６℃中低溫保存，可以使細(xì)胞暫時脫離生長狀態(tài)而將其細(xì)胞性保存起來，這樣在需要的時候再復(fù)蘇細(xì)胞用于實驗。而且適度地保存一定量的細(xì)胞，可以防止因正在培養(yǎng)的細(xì)胞被污染或其他意外事件而使細(xì)胞丟種，起到了細(xì)胞保種的作用。除此之外，還可以利用細(xì)胞凍存的形式來購買、寄贈、交換和運送某些細(xì)胞。細(xì)胞凍存時向培養(yǎng)基中加入保護劑--終濃度５%.１５%的甘油或二甲基亞砜(DMSO)，可使溶冰點降低，加之在緩慢凍結(jié)條件下，細(xì)胞內(nèi)水分透出，減少了冰晶形成，從而避免細(xì)胞損傷。 采用""慢凍快融""的方法能較HAO地保證細(xì)胞存活。標(biāo)準(zhǔn)冷凍速度開始為-１到-２℃/min，當(dāng)溫度低于-２５℃時可加速，到-８０℃之后可直接投入內(nèi)(-１９６℃)。

GTL16 Cells;背景說明：胃癌；肝轉(zhuǎn)移；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCI-H1184細(xì)胞、H-1341細(xì)胞、MBVP細(xì)胞

PAN 02 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MFM-223細(xì)胞、MTEC1細(xì)胞、RAW-264.7細(xì)胞

H2347 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：６傳代,每周２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：ChaGo-K1細(xì)胞、P388細(xì)胞、Centre Antoine Lacassagne-148細(xì)胞

mREC Cells;背景說明：視網(wǎng)膜；內(nèi)皮 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SKNBE(2c)細(xì)胞、16-HBE14o細(xì)胞、LLC-PK-1細(xì)胞

UT-7 Cells;背景說明：該細(xì)胞于１９８８年建系；源于一名６４歲患有急性粒細(xì)胞白血?。ˋMLM７）的男性的骨髓；對多種細(xì)胞因子有反應(yīng)。;傳代方法：維持細(xì)胞濃度在１.０-１.５×１０６cells/ml，１：２傳代，２-３天１次。;生長特性：懸浮生長，有１%~２%的細(xì)胞可輕微貼壁。;形態(tài)特性：圓形;相關(guān)產(chǎn)品有：HCCC-9810細(xì)胞、Panc_04_03細(xì)胞、FL62891細(xì)胞

LMTK- Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：ECV細(xì)胞、MUM2B細(xì)胞、MOLM-13細(xì)胞

EJ Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：Hepa-RG細(xì)胞、SNT8細(xì)胞、CORL105細(xì)胞

HFL 1 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長滿。;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞樣;相關(guān)產(chǎn)品有：MIA Paca2細(xì)胞、Panc 04.03細(xì)胞、HCC-1937細(xì)胞

DI-TNC1 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：成纖維母細(xì)胞樣;相關(guān)產(chǎn)品有：SN12CPM6細(xì)胞、Baby Hamster Kidney from litter No. 21細(xì)胞、hEM15A細(xì)胞

H711 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：IMCD-3細(xì)胞、SW 982細(xì)胞、MGHU3細(xì)胞

LM(TK-) Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HCC0015細(xì)胞、373 MG細(xì)胞、B/C3T3細(xì)胞

MKN-7 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：KM12 SM細(xì)胞、108CC15細(xì)胞、NR-8383細(xì)胞

CL 1-5 Cells;背景說明：肺腺癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：PANC-1細(xì)胞、H-1563細(xì)胞、IBMF-7細(xì)胞

SKLMS1 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：５傳代，２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：SCLC-21H細(xì)胞、PLA 802細(xì)胞、L5178Y TK+/-3.7.2c細(xì)胞

HT 29 Cells;背景說明：該細(xì)胞是１９６４年由FoghJ用移植培養(yǎng)方法和含１５%FBS的F１２培養(yǎng)液從原發(fā)性腫瘤分離的。近來，已建株的培養(yǎng)細(xì)胞用含血清的McCoy＇s５a培養(yǎng)基培養(yǎng)。該細(xì)胞系在裸鼠中成瘤，也能在類固醇處理的地鼠中成瘤。該細(xì)胞可合成IgA、CEA、TGFβ結(jié)合蛋白和黏液素；表達(dá)尿激酶受體，但沒有檢測到血漿酶原活性；不表達(dá)CD４，但細(xì)胞表面表達(dá)半乳糖神經(jīng)酰胺（HIV的可能替代受體）。該細(xì)胞系癌基因c-myc、K-ras、H-ras、N-ras、Myb、sis、fos陽性；p５３基因過表達(dá)，并且在２７３位密碼子處發(fā);傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：TM4細(xì)胞、G361-mel細(xì)胞、SRA01/04 (HLE)細(xì)胞

BT325 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：QGY細(xì)胞、J82細(xì)胞、HuH7細(xì)胞

MCF-7ADR Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Walker-Ca.256細(xì)胞、KASUMI1細(xì)胞、EJ 138細(xì)胞

HCT-15人結(jié)直腸腺癌復(fù)蘇細(xì)胞保種中心|帶STR證書

1F38 Cells(提供STR鑒定圖譜)

Abcam HeLa MTAP KO Cells(提供STR鑒定圖譜)

AG24131 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line RRG220 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XG951 Cells(提供STR鑒定圖譜)

C0888 Cells(提供STR鑒定圖譜)

CWR21 Cells(提供STR鑒定圖譜)

DA06446 Cells(提供STR鑒定圖譜)

GM00993 Cells(提供STR鑒定圖譜)

KU 812F Cells;背景說明：慢性粒細(xì)胞白血病；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：RPMI-8226S細(xì)胞、MRC-9細(xì)胞、HCC1171細(xì)胞

1.1B4 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：４傳代；每周２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮樣；多角形　;相關(guān)產(chǎn)品有：LN-18細(xì)胞、GM637A細(xì)胞、Human Kidney-2細(xì)胞

FET Cells;背景說明：結(jié)腸癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CTLL-2細(xì)胞、N-Tera-2細(xì)胞、H-1563細(xì)胞

COLO320/DM Cells;背景說明：該細(xì)胞可產(chǎn)生５-羥色胺、去甲、、ACTH和甲狀旁腺素。角蛋白、波形蛋白弱陽性。培養(yǎng)條件： RPMI １６４０  １０%FBS;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮+貼壁;形態(tài)特性：淋巴細(xì)胞;相關(guān)產(chǎn)品有：Pro-Lec1.3C細(xì)胞、Jurkat-FHCRC細(xì)胞、GOTO細(xì)胞

H-7721 Cells;背景說明：用Northernblot方法，未能檢測到細(xì)胞中１.３kbLFIRE-１/HFREP-１mRNA的表達(dá)。;傳代方法：１：３傳代，２-３天換液一次;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：TSU-Pr1細(xì)胞、TGBC-11-TKB細(xì)胞、HEp-2細(xì)胞

FHC Cells;背景說明：胎兒；結(jié)腸；自發(fā)永生；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HELA-GFP細(xì)胞、T-24細(xì)胞、S91細(xì)胞

30-C7 Cells(提供STR鑒定圖譜)

BV-2 Cells;背景說明：源于C５７BL/６小鼠小膠質(zhì)細(xì)胞，表達(dá)核v-myc、染色體v-raf癌基因，表面表達(dá)envgp７０抗原，在形態(tài)學(xué)、表型及功能上有吞噬細(xì)胞的特征。;傳代方法：１：６傳代；２-３天１次。;生長特性：半貼壁生長;形態(tài)特性：多形型;相關(guān)產(chǎn)品有：SKG IIIa細(xì)胞、INS1-E細(xì)胞、Mo7e細(xì)胞

Panc 1 Cells;背景說明：這株人胰腺癌細(xì)胞株源自于胰腺癌導(dǎo)管細(xì)胞，其倍增時間為５２小時。染色體研究表明，該細(xì)胞染色體眾數(shù)為６３，包括３個獨特標(biāo)記的染色體和１個小環(huán)狀染色體。該細(xì)胞的生長可被１unit/ml的左旋天冬酰胺酶抑制；能在軟瓊脂上生長；能在裸鼠上成瘤。;傳代方法：１：２-１：４傳代；每周２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮樣；多角形;相關(guān)產(chǎn)品有：PA317細(xì)胞、TE5細(xì)胞、OCI-Ly01細(xì)胞

PLC/PRF5 Cells;背景說明：該細(xì)胞系分泌乙肝病毒表面抗原（HBsAg）。 此細(xì)胞系原先被支原體污染，后用BM-cycline去除支原體;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：KYSE 510細(xì)胞、SUPB15細(xì)胞、LC1sq細(xì)胞

TE13 Cells;背景說明：食管鱗癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H1944細(xì)胞、GM05372細(xì)胞、CT26.CL25細(xì)胞

SHG 44 Cells;背景說明：SHG-４４細(xì)胞株源自一例２-３級前沿淋巴結(jié)星細(xì)胞瘤。染色體組型顯示８９.２%的超三倍體。在Wistar大鼠和裸鼠中接種都能成功。細(xì)胞含有神經(jīng)系統(tǒng)特有的S-１００蛋白和星細(xì)胞特有的GFA蛋白;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長滿。;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞樣;相關(guān)產(chǎn)品有：HD-LM-2細(xì)胞、Hs840T細(xì)胞、RT4-D6P2T細(xì)胞

JeKo 1 Cells;背景說明：一位套細(xì)胞淋巴瘤患者的巨細(xì)胞變種顯示白血病轉(zhuǎn)變，從其外周血單核細(xì)胞出發(fā)建立了MCL細(xì)胞株JeKo-１。 JeKo-１細(xì)胞EB病毒陰性，并表達(dá)一種B細(xì)胞表型的IgM。 細(xì)胞過表達(dá)cyclin D１, Bcl-２, c-Myc 及 Rb 蛋白。 Bcl-１/J(H)基因重排得到了PCR證實。 JeKo-１細(xì)胞在SCID小鼠中高成瘤。 [PubMed: ９７５３０６３];傳代方法：１：２傳代。３天內(nèi)可長滿。;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：HPAF-2細(xì)胞、TE-8細(xì)胞、hOMF細(xì)胞

VCaP Cells;背景說明：１９９７從一位不受激素影響的前列腺癌患者脊椎轉(zhuǎn)移灶中建立了這株細(xì)胞。先在小鼠中進行異種移植傳代，隨后進行體外培養(yǎng)。體內(nèi)及體外都對雄性激素敏感。;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長滿。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：Hs274T細(xì)胞、LNCaP-C4-2細(xì)胞、SKOV-3細(xì)胞

H-838 Cells;背景說明：該細(xì)胞于１９８４年建系，源于一位５９歲患有非小細(xì)胞肺癌的白人男性吸煙者，從患者淋巴結(jié)轉(zhuǎn)移灶分離而來。;傳代方法：１：３-１：６傳代；２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：CCLP-1細(xì)胞、ACC3細(xì)胞、IMR 90細(xì)胞

GM10149 Cells(提供STR鑒定圖譜)

HAP1 C1orf43 (-) 2 Cells(提供STR鑒定圖譜)

H2330 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MeT-5A細(xì)胞、OEC19細(xì)胞、hTERTHME1細(xì)胞

MRASMC Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Tohoku Hospital Pediatrics-1細(xì)胞、EC9706細(xì)胞、CCD-18Co細(xì)胞

BRL Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長滿。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：HEK293細(xì)胞、LAD 2細(xì)胞、Hs 445細(xì)胞

SUM-159 Cells;背景說明：乳腺癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCI-H1341細(xì)胞、HS5細(xì)胞、JurkatE6-1細(xì)胞

SUDHL1 Cells;背景說明：間變性大細(xì)胞淋巴瘤；胸腔積液轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：GC-1 spg細(xì)胞、ZR7530細(xì)胞、Huh 7.5.1細(xì)胞

JiyoyeP-2003 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：每周２-３次。;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：UCLA SO M14細(xì)胞、B5537SKIN細(xì)胞、Panc813細(xì)胞

MiaPaCa2 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代；;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HEC151細(xì)胞、CA 46細(xì)胞、KM12SM細(xì)胞

DB Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：每周換液２-３次。;生長特性：懸浮生長 ;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：RGB細(xì)胞、NBL-3細(xì)胞、HEL299細(xì)胞

HG03590 Cells(提供STR鑒定圖譜)

IDG-HEK293T-SCN2B-V5-OE Cells(提供STR鑒定圖譜)

LR-402 Cells(提供STR鑒定圖譜)

NCI-HPN-M1G Lung Cells(提供STR鑒定圖譜)

PathHunter U2OS TBXA2R beta-arrestin Cells(提供STR鑒定圖譜)

Ubigene A-549 CD63 KO Cells(提供STR鑒定圖譜)

UOK124LN Cells(提供STR鑒定圖譜)

HG01625 Cells(提供STR鑒定圖譜)

A-1847 Cells;背景說明：卵巢癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SL-29細(xì)胞、HuTu-80細(xì)胞、6-T CEM細(xì)胞

Panc 10.05 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：U373-MG細(xì)胞、CMT-93細(xì)胞、SNUC2A細(xì)胞

BRL3A Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：WEHI-164細(xì)胞、NTera-2D1細(xì)胞、COLO-205細(xì)胞

KBM-7/Hap8 Cells;背景說明：慢性髓原白血病；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HEP3B2細(xì)胞、GCT0404細(xì)胞、4T1-A細(xì)胞

MUM2B Cells;背景說明：脈絡(luò)膜黑色素瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：EL4細(xì)胞、H-187細(xì)胞、KP-N-RT-BM-1細(xì)胞

MUM2B Cells;背景說明：脈絡(luò)膜黑色素瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：EL4細(xì)胞、H-187細(xì)胞、KP-N-RT-BM-1細(xì)胞

HEK-293A Cells;背景說明：胚腎；腺病毒包裝;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：ECV-304細(xì)胞、U-373 MG細(xì)胞、KPL-4細(xì)胞

UMNSAH/DF-1 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：成纖維母細(xì)胞樣;相關(guān)產(chǎn)品有：NCM-460細(xì)胞、NCIH1666細(xì)胞、H-1993細(xì)胞

HL1 Cells;背景說明：心??；SV４０轉(zhuǎn)化;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：EM-3細(xì)胞、KU-812F細(xì)胞、Human Foreskin Fibroblast細(xì)胞

HBL100 Cells;背景說明：該細(xì)胞由E.V.Gaffney及其同事從一位沒有乳癌家族史的供者乳汁中建立，培養(yǎng)出來的細(xì)胞染色體組型在第７代時就不正常；電鏡照片顯示有微絲、張力原纖維和橋粒；Southern轉(zhuǎn)移表明有整合型SV４０病毒基因，當(dāng)作正常細(xì)胞。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：PLB985細(xì)胞、Mel RM細(xì)胞、SU-DHL-10細(xì)胞

MV 3 Cells;背景說明：黑色素瘤；淋巴結(jié)轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MDAMB361細(xì)胞、UCLA SO M21細(xì)胞、Stanford University Pediatric T-cell line 1細(xì)胞

MV-1-Lu Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：BIU-87/Adr細(xì)胞、NOZC-1細(xì)胞、T 98 G細(xì)胞

SK-OV-433 Cells;背景說明：卵巢癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：KYSE-450細(xì)胞、WIL2S細(xì)胞、DMS 273細(xì)胞

MA-782 Cells;背景說明：乳腺癌；Balb/c;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NKT細(xì)胞、AR41P細(xì)胞、UCLA SO M14細(xì)胞

PC-10 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCI-HUT-69細(xì)胞、NCIH2591細(xì)胞、P3X63NS1細(xì)胞

SC-1 [Mouse] Cells(提供STR鑒定圖譜)

NCI-H295 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCIH2141細(xì)胞、HUC-1細(xì)胞、Keio University-19-19細(xì)胞

Malme-3M Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：４傳代，２天換液１次。;生長特性：混合生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：NCI-H920細(xì)胞、HEK-EBNA細(xì)胞、Hs 343.T細(xì)胞

MBT-2 Cells;背景說明：膀胱移行細(xì)胞癌；C３H/He;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HEY-A8細(xì)胞、HT-1376細(xì)胞、EC109細(xì)胞

MX-1 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HFE-145細(xì)胞、Stanford University-Diffuse Histiocytic Lymphoma-8細(xì)胞、N-2a細(xì)胞

U373 MG Cells;背景說明：膠質(zhì)瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：D-341細(xì)胞、NUGC-4細(xì)胞、H-1395細(xì)胞

R2C Cells;背景說明：睪丸間質(zhì)瘤；雄性；Wistar Furth;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Y3-Ag1,2,3細(xì)胞、SW-620細(xì)胞、HOP-92細(xì)胞

L 1210 Cells;背景說明：該細(xì)胞源于用０.２%甲基膽蒽（溶解）涂抹雌性小鼠的皮膚誘發(fā)的腫瘤，鼠痘病毒陰性。;傳代方法：１：２傳代;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：BHP10-3細(xì)胞、NCI-SNU-5細(xì)胞、NCI-H2073細(xì)胞

H-510A Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：３-１：８傳代；每周換液２次。;生長特性：混合生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：HUT28細(xì)胞、Line 207細(xì)胞、McCoy細(xì)胞

AU565 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：４—１：６傳代；每３-５天換一次液。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：BV2細(xì)胞、COLO-741細(xì)胞、RL-952細(xì)胞

HEY-A8 Cells;背景說明：卵巢癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H1395細(xì)胞、D10細(xì)胞、VMRC-RCZ細(xì)胞

SNU-620 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：DoHH2細(xì)胞、RPMI 1846細(xì)胞、Hs 840.T細(xì)胞

H4-II-E Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Hmy.2 CIR細(xì)胞、NCI-H-295細(xì)胞、HCC44細(xì)胞

PE CA PJ34 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：J 111細(xì)胞、Sp2/0-Ag14細(xì)胞、SK Mel 1細(xì)胞

KNS-81 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：OUMS-23細(xì)胞、SW260細(xì)胞、OCILY10細(xì)胞

HCT-15人結(jié)直腸腺癌復(fù)蘇細(xì)胞保種中心|帶STR證書

BayGenomics ES cell line CSJ222 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line TEA073 Cells(提供STR鑒定圖譜)

CCRC-M147 Cells(提供STR鑒定圖譜)

M2-40 Cells(提供STR鑒定圖譜)

RL2 Cells(提供STR鑒定圖譜)

Shay Cells(提供STR鑒定圖譜)

" "PubMed=2041050; DOI=10.1093/jnci/83.11.757

Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D., Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

J. Natl. Cancer Inst. 83:757-766(1991)

PubMed=8464898; DOI=10.1073/pnas.90.7.2842; PMCID=PMC46192

Browning M.J., Krausa P., Rowan A.J., Bicknell D.C., Bodmer J.G., Bodmer W.F.

Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines.

Proc. Natl. Acad. Sci. U.S.A. 90:2842-2845(1993)

PubMed=7972006; DOI=10.1073/pnas.91.23.11045; PMCID=PMC45163

Okamoto A., Demetrick D.J., Spillare E.A., Hagiwara K., Hussain S.P., Bennett W.P., Forrester K., Gerwin B.I., Serrano M., Beach D.H., Harris C.C.

Mutations and altered expression of p16INK4 in human cancer.

Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994)

PubMed=8197130; DOI=10.1073/pnas.91.11.4751; PMCID=PMC43866

Bicknell D.C., Rowan A.J., Bodmer W.F.

Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors.

Proc. Natl. Acad. Sci. U.S.A. 91:4751-4755(1994)

PubMed=7621404; DOI=10.1016/0165-4608(94)00225-z

Chen T.-R., Dorotinsky C.S., McGuire L.J., Macy M.L., Hay R.J.

DLD-1 and HCT-15 cell lines derived separately from colorectal carcinomas have totally different chromosome changes but the same genetic origin.

Cancer Genet. Cytogenet. 81:103-108(1995)

PubMed=9000147

Cottu P.-H., Muzeau F., Estreicher A., Flejou J.-F., Iggo R.D., Thomas G., Hamelin R.

Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines.

Oncogene 13:2727-2730(1996)

PubMed=9000572

Hoang J.-M., Cottu P.-H., Thuille B., Salmon R.J., Thomas G., Hamelin R.

BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines.

Cancer Res. 57:300-303(1997)

PubMed=9809040; DOI=10.1016/S0165-4608(98)00081-8

Vermeulen S.J., Chen T.-R., Speleman F., Nollet F., Van Roy F.M., Mareel M.M.

Did the four human cancer cell lines DLD-1, HCT-15, HCT-8, and HRT-18 originate from one and the same patient?

Cancer Genet. Cytogenet. 107:76-79(1998)

PubMed=10700174; DOI=10.1038/73432

Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.

Systematic variation in gene expression patterns in human cancer cell lines.

Nat. Genet. 24:227-235(2000)

PubMed=10737795; DOI=10.1073/pnas.97.7.3352; PMCID=PMC16243

Rowan A.J., Lamlum H., Ilyas M., Wheeler J.M.D., Straub J., Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.

APC mutations in sporadic colorectal tumors: a mutational 'hotspot' and interdependence of the 'two hits'.

Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000)

PubMed=11314036; DOI=10.1038/sj.onc.1204211

Forgacs E., Wren J.D., Kamibayashi C., Kondo M., Xu X.L., Markowitz S.D., Tomlinson G.E., Muller C.Y., Gazdar A.F., Garner H.R., Minna J.D.

Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers.

Oncogene 20:1005-1009(2001)

PubMed=11414198; DOI=10.1007/s004320000207

Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.-J.

Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.

J. Cancer Res. Clin. Oncol. 127:375-386(2001)

PubMed=11416159; DOI=10.1073/pnas.121616198; PMCID=PMC35459

Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Short tandem repeat profiling provides an international reference standard for human cell lines.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)

PubMed=11526487; DOI=10.1038/sj.onc.1204611

Gayet J., Zhou X.-P., Duval A., Rolland S., Hoang J.-M., Cottu P.-H., Hamelin R.

Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines.

Oncogene 20:5025-5032(2001)

PubMed=11668190; DOI=10.1177/002215540104901105

Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.

Immunocytochemical analysis of cell lines derived from solid tumors.

J. Histochem. Cytochem. 49:1369-1378(2001)

PubMed=12584437; DOI=10.1159/000068544

Melcher R., Koehler S., Steinlein C., Schmid M., Mueller C.R., Luehrs H., Menzel T., Scheppach W., Moerk H., Scheurlen M., Koehrle J., Al-Taie O.

Spectral karyotype analysis of colon cancer cell lines of the tumor suppressor and mutator pathway.

Cytogenet. Genome Res. 98:22-28(2002)

PubMed=15748285; DOI=10.1186/1479-5876-3-11; PMCID=PMC555742

Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. 3rd, Stroncek D., Marincola F.M.

HLA class I and II genotype of the NCI-60 cell lines.

J. Transl. Med. 3:11.1-11.8(2005)

PubMed=15900046; DOI=10.1093/jnci/dji133

Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y., Yamazaki K., Hamada J.-i., Tada M., Moriuchi T., Ishikawa Y., Kato Y., Tomoda H., Yamori T., Tsuruo T.

p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.

J. Natl. Cancer Inst. 97:765-777(2005)

PubMed=16854228; DOI=10.1186/1476-4598-5-29; PMCID=PMC1550420

Bandres Elizalde E.M., Cubedo E., Agirre X., Malumbres R., Zarate R., Ramirez N., Abajo A., Navarro A., Moreno I., Monzo M., Garcia-Foncillas J.

Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues.

Mol. Cancer 5:29.1-29.10(2006)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433; PMCID=PMC2705832

Ikediobi O.N., Davies H.R., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Miroo T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=18167186; DOI=10.5555/cmj.0366-6999.120.23.p2119.01

Liu W.-D., Zhong B.-Y., Zhang Y.-D., Choi G.-S.

Mutation analysis of the checkpoint kinase 2 gene in colorectal cancer cell lines.

Chin. Med. J. 120:2119-2123(2007)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921; PMCID=PMC4020356

Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.

DNA fingerprinting of the NCI-60 cell line panel.

Mol. Cancer Ther. 8:713-724(2009)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

PubMed=20570890; DOI=10.1158/0008-5472.CAN-10-0192; PMCID=PMC2943514

Janakiraman M., Vakiani E., Zeng Z.-S., Pratilas C.A., Taylor B.S., Chitale D., Halilovic E., Wilson M., Huberman K., Ricarte Filho J.C.M., Persaud Y., Levine D.A., Fagin J.A., Jhanwar S.C., Mariadason J.M., Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.

Genomic and biological characterization of exon 4 KRAS mutations in human cancer.

Cancer Res. 70:5901-5911(2010)

PubMed=20606684; DOI=10.1038/sj.bjc.6605780; PMCID=PMC2920028

Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.

5-fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency.

Br. J. Cancer 103:340-346(2010)

PubMed=22068913; DOI=10.1073/pnas.1111840108; PMCID=PMC3219108

Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.

Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)

PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017

Kong D.-X., Yamori T.

JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.

Bioorg. Med. Chem. 20:1947-1951(2012)

PubMed=22347499; DOI=10.1371/journal.pone.0031628; PMCID=PMC3276511

Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.

Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.

PLoS ONE 7:E31628-E31628(2012)

PubMed=22384151; DOI=10.1371/journal.pone.0032096; PMCID=PMC3285665

Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.

Identification of cancer cell-line origins using fluorescence image-based phenomic screening.

PLoS ONE 7:E32096-E32096(2012)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

PubMed=22628656; DOI=10.1126/science.1218595; PMCID=PMC3526189

Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.

Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.

Science 336:1040-1044(2012)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342; PMCID=PMC4893961

Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

Cancer Res. 73:4372-4382(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018

Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C., Wilhelm M., Kuster B.

Global proteome analysis of the NCI-60 cell line panel.

Cell Rep. 4:609-620(2013)

PubMed=24042735; DOI=10.1038/oncsis.2013.35; PMCID=PMC3816225

Ahmed D., Eide P.W., Eilertsen I.A., Danielsen S.A., Eknaes M., Hektoen M., Lind G.E., Lothe R.A.

Epigenetic and genetic features of 24 colon cancer cell lines.

Oncogenesis 2:e71.1-e71.8(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20; PMCID=PMC4178206

Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.

The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.

Cancer Metab. 1:20.1-20.13(2013)

PubMed=24670534; DOI=10.1371/journal.pone.0092047; PMCID=PMC3966786

Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.

High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.

PLoS ONE 9:E92047-E92047(2014)

PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013

Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S., Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S., O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F., Mariadason J.M., Sieber O.M.

Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.

Cancer Res. 74:3238-3247(2014)

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

PubMed=25926053; DOI=10.1038/ncomms8002

Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G., Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S., Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M., Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.

Nat. Commun. 6:7002.1-7002.10(2015)

PubMed=25944804; DOI=10.1158/1078-0432.CCR-14-2457

Bazzocco S., Dopeso H., Carton-Garcia F., Macaya I., Andretta E., Chionh F., Rodrigues P., Garrido M., Alazzouzi H., Nieto R., Sanchez A., Schwartz S. Jr., Bilic J., Mariadason J.M., Arango D.

Highly expressed genes in rapidly proliferating tumor cells as new targets for colorectal cancer treatment.

Clin. Cancer Res. 21:3695-3704(2015)

PubMed=26169745; DOI=10.1186/s12967-015-0576-z; PMCID=PMC4499939

Halama A., Guerrouahen B.S., Pasquier J., Diboun I., Karoly E.D., Suhre K., Rafii A.

Metabolic signatures differentiate ovarian from colon cancer cell lines.

J. Transl. Med. 13:223.1-223.12(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Genome Med. 7:118.1-118.7(2015)

PubMed=26537799; DOI=10.1074/mcp.M115.051235; PMCID=PMC4762531

Holst S., Deuss A.J.M., van Pelt G.W., van Vliet S.J., Garcia-Vallejo J.J., Koeleman C.A.M., Deelder A.M., Mesker W.E., Tollenaar R.A.E.M., Rombouts Y., Wuhrer M.

N-glycosylation profiling of colorectal cancer cell lines reveals association of fucosylation with differentiation and caudal type homebox 1 (CDX1)/villin mRNA expression.

Mol. Cell. Proteomics 15:124-140(2016)

PubMed=27377824; DOI=10.1038/sdata.2016.52; PMCID=PMC4932877

Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.

Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.

Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4; PMCID=PMC5087121

Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.

A map of mobile DNA insertions in the NCI-60 human cancer cell panel.

Mob. DNA 7:20.1-20.11(2016)

PubMed=28179481; DOI=10.1158/1535-7163.MCT-16-0578

Tanaka N., Mashima T., Mizutani A., Sato A., Aoyama A., Gong B., Yoshida H., Muramatsu Y., Nakata K., Matsuura M., Katayama R., Nagayama S., Fujita N., Sugimoto Y., Seimiya H.

APC mutations as a potential biomarker for sensitivity to tankyrase inhibitors in colorectal cancer.

Mol. Cancer Ther. 16:752-762(2017)

PubMed=28192450; DOI=10.1371/journal.pone.0171435; PMCID=PMC5305277

Fasterius E., Raso C., Kennedy S.A., Rauch N., Lundin P., Kolch W., Uhlen M., Al-Khalili Szigyarto C.

A novel RNA sequencing data analysis method for cell line authentication.

PLoS ONE 12:E0171435-E0171435(2017)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=28683746; DOI=10.1186/s12943-017-0691-y; PMCID=PMC5498998

Berg K.C.G., Eide P.W., Eilertsen I.A., Johannessen B., Bruun J., Danielsen S.A., Bjornslett M., Meza-Zepeda L.A., Eknaes M., Lind G.E., Myklebost O., Skotheim R.I., Sveen A., Lothe R.A.

Multi-omics of 34 colorectal cancer cell lines -- a resource for biomedical studies.

Mol. Cancer 16:116.1-116.16(2017)

PubMed=28854368; DOI=10.1016/j.celrep.2017.08.010; PMCID=PMC5583477

Roumeliotis T.I., Williams S.P., Goncalves E., Alsinet C., Del Castillo Velasco-Herrera M., Aben N., Ghavidel F.Z., Michaut M., Schubert M., Price S., Wright J.C., Yu L., Yang M., Dienstmann R., Guinney J.H., Beltrao P., Brazma A., Pardo M., Stegle O., Adams D.J., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.

Genomic determinants of protein abundance variation in colorectal cancer cells.

Cell Rep. 20:2201-2214(2017)

PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051; PMCID=PMC6343826

Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W., Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D.A., Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E., Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C., Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H., McCormick F.

Differential effector engagement by oncogenic KRAS.

Cell Rep. 22:1889-1902(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9

Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Nature 568:511-516(2019)"